tocilizumab,obinutuzumab,glofitamab
jw pharma,roche
['lymsm', 'glofitamab', 'lymphoma', 'leusm']
congress|#17icml
carmelo carlo-stella, presents data showing high efficacy and a manageable safety profile of fixed duration glofitamab in pts with richter's transformation (rt)
- best response: orr of 63.6% &amp; cr of 45.5%
- crs were durable
#lymsm #leusm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm